Sigma Planning Corp Cuts Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Sigma Planning Corp decreased its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 2.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 10,540 shares of the biotechnology company’s stock after selling 309 shares during the period. Sigma Planning Corp’s holdings in Sarepta Therapeutics were worth $1,282,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Blue Trust Inc. grew its holdings in Sarepta Therapeutics by 896.5% during the third quarter. Blue Trust Inc. now owns 568 shares of the biotechnology company’s stock worth $71,000 after acquiring an additional 511 shares during the period. International Assets Investment Management LLC boosted its position in shares of Sarepta Therapeutics by 59,222.7% during the 3rd quarter. International Assets Investment Management LLC now owns 75,933 shares of the biotechnology company’s stock worth $9,483,000 after purchasing an additional 75,805 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Sarepta Therapeutics by 112.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,002 shares of the biotechnology company’s stock worth $747,000 after purchasing an additional 3,180 shares during the period. State of Alaska Department of Revenue increased its holdings in shares of Sarepta Therapeutics by 7.3% in the 3rd quarter. State of Alaska Department of Revenue now owns 11,035 shares of the biotechnology company’s stock valued at $1,378,000 after purchasing an additional 750 shares in the last quarter. Finally, Riggs Asset Managment Co. Inc. lifted its stake in shares of Sarepta Therapeutics by 666.7% in the third quarter. Riggs Asset Managment Co. Inc. now owns 2,300 shares of the biotechnology company’s stock valued at $287,000 after purchasing an additional 2,000 shares during the period. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Sarepta Therapeutics Stock Performance

NASDAQ SRPT opened at $105.56 on Tuesday. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The company has a market capitalization of $10.08 billion, a PE ratio of 84.45 and a beta of 0.75. The business’s 50-day moving average price is $117.11 and its 200 day moving average price is $123.14. Sarepta Therapeutics, Inc. has a twelve month low of $101.15 and a twelve month high of $173.25.

Insider Buying and Selling

In other news, Director Kathryn Jean Boor sold 1,636 shares of Sarepta Therapeutics stock in a transaction dated Thursday, December 5th. The stock was sold at an average price of $125.55, for a total value of $205,399.80. Following the transaction, the director now directly owns 5,880 shares of the company’s stock, valued at $738,234. The trade was a 21.77 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the business’s stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $124.84, for a total value of $1,310,820.00. Following the sale, the director now owns 22,840 shares of the company’s stock, valued at $2,851,345.60. The trade was a 31.49 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 7.70% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have weighed in on SRPT. Cantor Fitzgerald upgraded shares of Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and upped their target price for the stock from $152.00 to $167.00 in a research report on Thursday, November 7th. Deutsche Bank Aktiengesellschaft began coverage on Sarepta Therapeutics in a report on Tuesday, February 11th. They issued a “hold” rating and a $136.00 price target on the stock. Piper Sandler reduced their price objective on Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating for the company in a report on Wednesday, November 27th. Needham & Company LLC reissued a “buy” rating and issued a $202.00 target price on shares of Sarepta Therapeutics in a report on Monday, January 27th. Finally, Robert W. Baird dropped their price target on Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a research report on Thursday, November 7th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $176.77.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.